Product Wiki · Recalls · EU Safety Gate (RAPEX)

NATURAL GLOW CLARIFYNG CREAM — recall SR/00965/25

EU Safety Gate (RAPEX) · United Kingdom in respect of Northern Ireland · 2025-03-14 · Serious risk

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
SR/00965/25
Date of alert
2025-03-14
Country / jurisdiction
United Kingdom in respect of Northern Ireland
Risk level
Serious risk
Risk type
Chemical
Brand
Carotone
Product category
Cosmetics
Product type
Skin lightening cream
Reported risk: The product contains hydroquinone and clobetasol propionate (measured value: 3.7% and 0.01%, respectively), which are prohibited in cosmetic products. Hydroquinone may cause an allergic skin reaction and might cause cancer and causes serious eye damage. Clobetasol propionate is a corticosteroid that should only be applied if medically prescribed. Exposure to it could cause skin irritation and may lead to endocrine problems.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator to whom the measure were ordered
Importer
Category of measure
Destruction of the product
Date of entry into force
10/09/2024
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10093513

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.